Zota Healthcare gets registration licenses for 5 products

Zota Healthcare Limited has received product registration licenses for five products from Turkmenistan. The said products are mentioned below:

Under the leukotriene receptor antagonists category, MoNTIZED - 10 has got the license. It is available as tablets and each tablet contains Montelukast 10mg. The second product is ZOTAMET 1000, available as tablets and contains Metformin 1000mg. It has gained the license under the antidiabetic category. Other three products include ROSUNA 5, 10, and 20, all of which are available as tablets, containing Rosuvastatin 5mg, 10mg, and 20mg, respectively. These products achieved licenses under the anti-hyperlipidemic category.

These licenses have validity period of five years and are renewable. The company would start exporting these products in Turkmenistan very soon.

Earlier in the month of November, Zota Healthcare had received registration licenses for three products. Under the angiotensin receptor blocker category, it got license for CDTEL-H (Tablet - Each tablet contains Telmisartan 40 MG + Hydrochlorothiazide 12.5 MG). Under the leukotriene receptor antagonists category, it gained license for MONTIZED - L (Tablet - Each tablet contains Levocetirizine 5 mg + Montelukast 10 mg), and under the Alpha Blocker category, it got license for TAMZED -0.4 (Capsule - Each hard gelatin capsule contains Tamsulosin Hydrochloride 0.4mg.)

On Thursday, the stock of Zota Healthcare was trading at Rs 191.00, up by 0.32 per cent from its previous close of Rs 190.40 on NSE.